Currently out of the existing stock ratings of Whitney Ijem, 124 are a BUY (80.52%), 23 are a HOLD (14.94%), 7 are a SELL (4.55%).

Whitney Ijem

Work Performance Price Targets & Ratings Chart

Analyst Whitney Ijem, currently employed at CANACCORD, carries an average stock price target met ratio of 42.68% that have a potential upside of 35.52% achieved within 371 days. Previously, Whitney Ijem worked at GUGGENHEIM.

Whitney Ijem’s has documented 299 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on NTLA, Intellia Therapeutics at 16-Jun-2026.

Wall Street Analyst Whitney Ijem

Analyst best performing recommendations are on PASG (PASSAGE BIO).
The best stock recommendation documented was for PASG (PASSAGE BIO) at 9/17/2024. The price target of $13 was fulfilled within 6 days with a profit of $1.54 (10.59%) receiving and performance score of 17.65.

Average potential price target upside

SRPT Sarepta Therapeutics GBIO Generation Bio Co PASG Passage Bio RCKT Rocket Pharmaceuticals RGLS Regulus Therapeutics TNYA Tenaya Therapeutics ALNY Alnylam Pharmaceuticals BMRN Biomarin Pharmaceutical GILD Gilead Sciences KRYS Krystal Biotech RYTM Rhythm Pharmaceuticals SGMO Sangamo Therapeutics TSHA Taysha Gene Therapies  VRTX Vertex Pharmaceuticals ARCT Arcturus Therapeutics Holdings NTLA Intellia Therapeutics SGTX Sigilon Therapeutics  VERV Verve Therapeutics RARE Ultragenyx AXGT Sio Gene Therapies ONCE Spark Therapeutics WVE Wave Life Sciences Ltd GUTS Fractyl Health, Common Stock AVRO AVROBIO

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 23-Jun-2025

$20

$4.32 (27.55%)

$16

17 days ago
(09-Jul-2026)

7/17 (41.18%)

$-0.52 (-2.53%)

71

Sell Since 24-Jul-2025

$13

$-3.85 (-22.85%)

4 months ago
(26-Mar-2026)

0/2 (0%)

$-8.68 (-40.04%)

Sell Since 22-Jul-2025

4 months ago
(26-Mar-2026)

14/35 (40%)

$28.03 (127.58%)

364

Buy Since 19-Mar-2026

$37

$20.15 (119.58%)

$50

4 months 7 days ago
(19-Mar-2026)

0/16 (0%)

$20.35 (122.22%)

Buy Since 13-Mar-2026

$31

$14.15 (83.98%)

$19

4 months 13 days ago
(13-Mar-2026)

4/14 (28.57%)

$14.6 (89.02%)

322

Show more analysts

Please expand the browser size to see the chart

Which stock is Whitney Ijem is most bullish on?

Potential upside of $157.23 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Whitney Ijem is most reserved on?

Potential downside of -$41.36 has been obtained for VRTX (VERTEX PHARMACEUTICALS)

What Year was the first public recommendation made by Whitney Ijem?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?